Clinical Trial Update: Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing doxorubicin alone, atezolizumab alone, and the combination in recurrent cervical cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Cervical Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING